Key takeaways
- • Anthem BCBS commercial GLP-1 coverage is highly plan-specific — same drug, same prescriber, different employer group can mean covered or excluded; verify with your specific plan and current formulary
- • T2D-indicated GLP-1s (Ozempic, Mounjaro, Rybelsus) are generally on Anthem commercial formularies with prior authorization requiring documented Type 2 diabetes; verify with your specific plan and current formulary
- • Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda) are frequently excluded by self-funded employer (ASO) plans Anthem administers — the employer chooses the benefit, not Anthem; check your benefit summary for an AOM exclusion
- • Prior authorization is nearly universal — expect to document BMI, comorbidities, prior lifestyle intervention, and (for T2D drugs) diabetes diagnosis with A1c
- • Appeals work best with thorough clinical documentation and external independent review for medical-necessity denials; benefit-exclusion denials require an employer plan-design change, not a clinical appeal
How Anthem Blue Cross Blue Shield approaches GLP-1 coverage
Anthem Blue Cross Blue Shield operates across 14 states and administers both fully-insured commercial plans and self-funded employer (ASO) plans. For T2D-indicated GLP-1s like Ozempic, Mounjaro, and Rybelsus, Anthem commercial formularies generally include them with prior authorization requiring documented Type 2 diabetes diagnosis (ICD-10 codes, A1c results) — but tier placement, step therapy, and quantity limits vary by plan; verify with your specific plan and current formulary. For weight-loss-indicated GLP-1s (Wegovy, Zepbound, Saxenda), coverage is highly plan-dependent: some Anthem commercial plans cover them with PA requiring BMI greater than or equal to 30 (or greater than or equal to 27 with comorbidities) plus documented lifestyle intervention, while many self-funded employer groups exclude anti-obesity medications entirely as a benefit design choice. Always verify your specific plan's drug list and any AOM (anti-obesity medication) rider with member services before assuming coverage.
Statutory and structural notes
Anthem commercial plans are not bound by the Medicare Part D weight-loss-drug exclusion (SSA §1860D-2(e)(2)(A)). ACA essential health benefits do NOT require weight-loss drug coverage, so Marketplace and group plans may legally exclude AOMs. Self-funded ERISA plans Anthem administers (ASO) have benefit design controlled entirely by the employer plan sponsor — Anthem only adjudicates per the plan document. State mandates vary. Verify your specific plan's benefit summary.
Typically considered for coverage
The list below reflects general patterns observed across Anthem Blue Cross Blue Shieldplan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.
- Ozempic (semaglutide) for T2D — generally on formulary with PA requiring diabetes documentation; tier and step therapy vary by plan, verify with your specific plan and current formulary
- Mounjaro (tirzepatide) for T2D — typically covered with PA, often step therapy through metformin first; verify with your specific plan and current formulary
- Rybelsus (oral semaglutide) for T2D — usually formulary-listed with PA; verify with your specific plan and current formulary
- Trulicity (dulaglutide) and Victoza (liraglutide) for T2D — commonly covered with PA; verify with your specific plan and current formulary
- Wegovy (semaglutide) for weight management — may be covered on plans that include AOM benefit with PA (BMI ≥30 or ≥27 with comorbidity plus lifestyle program); many employer plans exclude — verify with your specific plan and current formulary
- Zepbound (tirzepatide) for weight management or OSA — coverage varies widely; PA universally required when covered; verify with your specific plan and current formulary
Typically excluded
- Wegovy, Zepbound, Saxenda for weight loss under self-funded employer plans that have elected to exclude anti-obesity medications (common across large ASO employer groups)
- Off-label use of T2D GLP-1s (Ozempic, Mounjaro, Rybelsus) for weight loss without a T2D diagnosis — denied as not medically necessary
- Compounded semaglutide and tirzepatide — generally not covered; Anthem follows FDA guidance treating compounded versions as not FDA-approved
- Concurrent use of two GLP-1 receptor agonists — excluded per clinical policy
- GLP-1s for patients not meeting documented BMI, comorbidity, or prior lifestyle intervention criteria in the plan's PA policy
Prior authorization
Prior authorization is commonly required for GLP-1 medications under Anthem Blue Cross Blue Shield plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.
Appeal strategy if denied
File a Level 1 internal appeal within 180 days with BMI history, A1c, comorbidities, prior weight-loss attempts, and failed alternatives. Escalate to Level 2 if upheld, then request Independent External Review through your state (binding for medical-necessity denials; ERISA self-funded plans use federal appeal rights). Attach a letter of medical necessity. For employer-exclusion denials, ask HR to add an AOM rider — clinical appeals cannot override a benefit exclusion.
GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.